Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide

By afschroeder • June 9, 2026

Olson TE, Lloyd TS, Hamad CD, Chun RF, Wiener J, Golzar A, Mehany J, Shahamatdar S, Kittredge A, Pearce L, Francis KP, Obeidin F, Holly LT, Yeaman MR, Adams JS, Bernthal NM, Sheppard WL. Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide. JOR Spine. 2026 May 28;9(2):e70196. doi: 10.1002/jsp2.70196. PMID: 42253285; PMCID: PMC13239351.

Tags: cytokine profile, Harbor UCLA, immune dysregulation, Infectious Diseases, metabolic intervention, murine model, Publications, spinal implant‐associated infection, type 1 diabetes mellitus, Type 2 diabetes mellitus, wound healing

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with[...]

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280.[...]